Patients with osteoporosis who took bisphosphonates, especially risedronate, were at a higher risk of developing acute angle ...

In the course of evaluating the optimal duration of bisphosphonate treatment the FDA found little benefit of treatment beyond 5 years. [1,2] Moreover, examination of studies where bisphosphonates ...

Examination of the patient and review of the bone specimen. Diagnosis. Giant osteoclasts after long-term bisphosphonate use, without evidence of malignancy. Management. Interpretation of the bone ...

"Among dialysis patients with osteoporosis, denosumab may be more effective than oral bisphosphonates in reducing fracture ...

Denosumab has greater preventive effect on fractures, but increased risk for MACE compared with oral bisphosphonates.

If you've been given a diagnosis of osteoporosis your doctor will probably prescribe a bisphosphonate, a class of drugs that helps preserve and build bone. Alendronate (Fosamax, Fosamax Plus D ...

No dedicated clinical trials have compared denosumab and bisphosphonates for fracture prevention in patients on dialysis.